Wellington Management Group LLP Raises Stake in CVS Health Corporation $CVS

Wellington Management Group LLP increased its holdings in shares of CVS Health Corporation (NYSE:CVS) by 49.8% during the 2nd quarter, HoldingsChannel reports. The fund owned 33,801,113 shares of the pharmacy operator’s stock after buying an additional 11,233,381 shares during the period. CVS Health accounts for approximately 0.6% of Wellington Management Group LLP’s portfolio, making the stock its 25th biggest holding. Wellington Management Group LLP’s holdings in CVS Health were worth $3,496,725,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also made changes to their positions in CVS. Caitong International Asset Management Co. Ltd boosted its position in shares of CVS Health by 407.2% in the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 350 shares of the pharmacy operator’s stock worth $26,000 after purchasing an additional 281 shares in the last quarter. Swiss RE Ltd. bought a new position in CVS Health during the 4th quarter valued at approximately $26,000. Kilter Group LLC purchased a new position in CVS Health during the second quarter valued at $27,000. Sankala Group LLC bought a new stake in CVS Health in the fourth quarter worth $28,000. Finally, Global Trust Asset Management LLC raised its position in shares of CVS Health by 344.8% in the 1st quarter. Global Trust Asset Management LLC now owns 387 shares of the pharmacy operator’s stock worth $28,000 after purchasing an additional 300 shares during the last quarter. Institutional investors own 80.66% of the company’s stock.

More CVS Health News

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: Pharmacy momentum supports the turnaround case. Rising prescription volumes, gains associated with Rite Aid and improving pharmacy profitability could provide support for CVS’s second-half outlook. This adds to the company’s recent earnings momentum, including revenue growth and an earnings beat in its latest reported quarter. How CVS’ Pharmacy and Consumer Wellness Is Positioned for H2 2026
• Positive Sentiment: Updated flu vaccines are now available nationwide. CVS Pharmacy and MinuteClinic are offering the 2026–2027 vaccines, while expanded testing and treatment services may increase seasonal customer traffic. A company survey found that more than 60% of consumers are likely to get a flu shot, though the earnings effect is likely to be seasonal and modest. CVS Pharmacy and MinuteClinic Now Offering Updated Flu Vaccines Nationwide
• Positive Sentiment: Value-focused coverage is reinforcing rebound expectations. Zacks characterizes CVS as a potential long-term value stock, while Trefis notes that the company’s historical drawdowns have often eventually recovered. These are sentiment and valuation arguments rather than new financial guidance, but they may attract investors seeking a healthcare turnaround at a relatively reasonable valuation. Why CVS Health Is a Top Value Stock for the Long-Term
• Neutral Sentiment: ACA insurer exits create both opportunity and uncertainty. Cigna, Molina and other carriers are leaving Obamacare exchanges in 2027. The disruption could create enrollment opportunities for Aetna, CVS’s insurance business, but also highlights regulatory, pricing and membership risks across the sector. All the Insurers Exiting ACA Obamacare Exchanges for 2027
• Negative Sentiment: Political pressure on vertically integrated healthcare companies remains a risk. Mark Cuban’s support for breaking up “big medicine” adds to scrutiny of insurers, pharmacy benefit managers and large healthcare platforms. No specific policy action against CVS was announced, but potential structural or regulatory changes could weigh on sentiment. Mark Cuban Backs Plan to Break Up Big Medicine

CVS Health Trading Up 0.2%

Shares of NYSE:CVS opened at $93.15 on Friday. The stock’s 50-day simple moving average is $101.42 and its two-hundred day simple moving average is $89.46. The stock has a market capitalization of $119.14 billion, a price-to-earnings ratio of 24.64, a PEG ratio of 0.91 and a beta of 0.61. CVS Health Corporation has a 52-week low of $69.51 and a 52-week high of $110.68. The company has a debt-to-equity ratio of 0.74, a quick ratio of 0.66 and a current ratio of 0.87.

CVS Health (NYSE:CVS) last released its quarterly earnings results on Wednesday, August 5th. The pharmacy operator reported $2.58 EPS for the quarter, beating the consensus estimate of $1.87 by $0.71. CVS Health had a net margin of 1.18% and a return on equity of 13.12%. The firm had revenue of $106.10 billion during the quarter, compared to analyst estimates of $100.03 billion. During the same quarter in the prior year, the firm earned $1.81 EPS. The business’s revenue for the quarter was up 7.3% compared to the same quarter last year. CVS Health has set its FY 2026 guidance at 7.900-8.100 EPS. Analysts expect that CVS Health Corporation will post 8.02 EPS for the current year.

CVS Health Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, August 3rd. Shareholders of record on Thursday, July 23rd were issued a dividend of $0.665 per share. This represents a $2.66 dividend on an annualized basis and a yield of 2.9%. The ex-dividend date of this dividend was Thursday, July 23rd. CVS Health’s dividend payout ratio is currently 70.37%.

Analysts Set New Price Targets

Several research firms recently commented on CVS. Royal Bank Of Canada increased their price objective on CVS Health from $107.00 to $113.00 and gave the company an “outperform” rating in a research report on Thursday, July 9th. TD Cowen upped their target price on shares of CVS Health from $105.00 to $110.00 and gave the company a “buy” rating in a research note on Monday, May 11th. Deutsche Bank Aktiengesellschaft raised their price target on shares of CVS Health from $88.00 to $92.00 and gave the company a “buy” rating in a report on Thursday, May 7th. Bank of America boosted their price objective on shares of CVS Health from $100.00 to $110.00 and gave the company a “buy” rating in a report on Monday, June 22nd. Finally, Sanford C. Bernstein increased their price objective on shares of CVS Health from $94.00 to $106.00 and gave the company an “outperform” rating in a research report on Tuesday, May 12th. Twenty-two investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $107.17.

About CVS Health

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.